Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 4/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 4/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408757 | 0.96 | AR (0.43) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL410468 | 0.84 | AR (0.43) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL410398 | 0.84 | GFER (0.41) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL407058 | 0.80 | AR (0.39) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL11106979 | 0.77 | GFER (0.57) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL27828825 | 0.76 | KDM4E (0.46) | GFERTP53MAPTPOLBALDH1A1 | |
| SCHEMBL411118 | 0.75 | GFER (0.46) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL6103009 | 0.72 | GFER (0.46) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL6103013 | 0.72 | GFER (0.46) | GFERSMARCA2SMARCA4PBRM1NR1I2 | |
| SCHEMBL27851609 | 0.71 | KDM4E (0.43) | GFERARTSHRDRD2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| EP-2376484-B1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO SA (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8815919-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791142-B2 | Oxazole pyridine derivatives useful as S1P1 receptor agonists | MERCK SERONO S.A. (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8741923-B2 | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis | MERCK SERONO SA (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO SA (CH) | 2011-12-15 | — | — | US | disclosed |
| EP-2376484-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Merck Serono S.A. (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20110230518-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2011-09-22 | — | — | US | disclosed |
| WO-2010115751-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100142-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010069949-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2010-06-24 | — | — | WO | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | GFER 826/4885SMARCA2 1736/4885SMARCA4 1334/4885 |
| US-20110230518-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, AQP4, NDUFS3 | GFER 1596/4885SMARCA2 2843/4885SMARCA4 2249/4885 |
| US-20110306636-A1 | OXAZOLE PYRIDINE DERIVATIVES USEFUL AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR5 | GFER 2370/4885SMARCA2 2808/4885SMARCA4 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.